Table 4.
The concentrations (pg/mL) of MCP-1, TGF-β2, and VEGF in three types of PCD and control groups as median (25th, 75th).
| Type I | Type II | Type III | Control group | P-value | |
|---|---|---|---|---|---|
| N (Eyes) | 18 | 14 | 9 | ||
| MCP-1 | 1530.30 (620.12, 2473.32) | 1425.09 (934.90, 2030.85) | 1147.51 (730.60, 2154.90) | 767.40(583.78, 1039.74) | 0.340 |
| TGF-β2 | 3357.62 (2425.43, 4511.84) | 2540.45 (1059.82, 5753.14) | 2446.96 (1810.64, 4947.94) | 1808.76 (951.66, 3579.52) | 0.359 |
| VEGF | 87.24 (51.75, 284.70) | 213.15 (82.93, 301.33) | 132.93 (95.66, 318.49) | 97.20 (59.30, 135.61) | 0.186 |
Type I: large defect with sinking cortex in anterior vitreous. Type II: reticular defect or cluster of fibrotic spots in posterior capsule. Type III: posterior capsule defect with concurrent PFV. The Kruskal-Wallis test demonstrated that the differences of MCP-1, TGF-β2, and VEGF levels in three types of PCD were no statistically significant.